Advancing Psychedelics Research and Development

Developing a pipeline of patent pending, cost effective cGMP psychedelic compounds for the furtherance of mental health and neurological disorders research.

We're creating a new approach for dealing with mental health and addiction

Core One Labs is a Canadian life sciences biotechnology company focused on research, development, and production of biologically synthesized (biosynthesized) cGMP API grade psychedelic compounds, as well as the advancement of psychedelic assisted modalities for the treatment of various mental health and neurological disorders.


The Company’s shares trade on the Canadian Securities Exchange (“CSE”) under the trading symbol “COOL,” on the OTC under the trading symbol “CLABF,” and on the Borse Frankfurt Exchange under the symbol “LD6, WKN: A3CSSU”.

Our Leadership Team

Dr. Robert Hancock

Executive Chairman

Dr. Hancock a world-leading microbiologist and has researched and taught at the University of British Columbia for nearly 40 years.

He has published more than 670 papers and reviews, is an ISI highly cited author in Microbiology with more than 63,000 citations and an h-index of 134, and has 55 patents awarded.

Hancock has trained to date 140 Graduate Students and Postdoctoral Fellows and won the Killam Prize for excellence in Mentoring in 2010. Those trainees who graduated are currently employed in a variety of positions covering a gamut from academia to industry to government laboratories.

In recognition of his work, Dr. Hancock has received numerous awards and honours including: the Prix Galien (Highest Award for Canadian Pharmaceutical Research and Innovation), the Killam Prize (Canada Council’s prize for Health Research), Michael Smith CIHR Researcher of the Year, the ICAAC Aventis Antimicrobial Research Award (Leading award worldwide for antimicrobial research) and in 2001 he was inducted as an Officer of the Order of Canada (Canada’s second highest honour).

He is the co-founder of Migenix, Inimex Pharmaceuticals, ABT Innovations, Sepset and the Centre for Drug Research and Development.

Joel Shacker

Chief Executive Officer

Mr. Shacker has worked extensively in the cannabis and finance space over the last 7 years. During his time as the CEO of Thoughtful Brands Inc, a vertically integrated ecommerce cannabis company, Mr.Shacker led the company from a non revenue generating entity, to one that generates over $30,000,000 per year. He has overseen operations across North America, Europe, Central America and South America. Mr. Shacker has been on the board of numerous public companies which have collectively raised over $50,000,000. His expertise in the emerging medical cannabis market, coupled with his business acumen to implement successful growth strategies, has allowed him to become one of the top young CEO’s in the public markets. He has acquired and integrated over 20 different assets across multiple industries, resulting in over $150,000,000 in acquisitions over his career.

Jan Burian

Chief Technical Officer at Vocan Biotechnologies

Dr. Burian is a successful biochemist and molecular biologist with extensive knowledge in operations, scale-up of fermentative API-production, research and development. He has numerous academic publications to his name. He previously held a site directorship with Pfizer.